Advertisement
Advertisement
U.S. markets open in 7 hours 41 minutes
S&P Futures
4,150.25 +8.50 (+0.21%) Dow Futures
32,853.00 +61.00 (+0.19%) Nasdaq Futures
13,207.25 +24.00 (+0.18%) Russell 2000 Futures
1,946.10 +5.00 (+0.26%) Crude Oil
90.82 +0.06 (+0.07%) Gold
1,802.40 -2.80 (-0.16%)
Tetra Bio-Pharma Inc. (JAM1.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:00AM CEST
Advertisement
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.0450 |
| Open | 0.0450 |
| Bid | 0.0358 x 4074100 |
| Ask | 0.0646 x 2558200 |
| Day's Range | 0.0450 - 0.0450 |
| 52 Week Range | 0.0270 - 0.2220 |
| Volume | |
| Avg. Volume | 89 |
| Market Cap | 20.864M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings Date | Jul 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Subscribe to Yahoo Finance Plus to view Fair Value for JAM1.F
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Business Wire
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
LONDON & MONTREAL, July 12, 2022--Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form for global commercialization of Tetra’s QIXLEEF.
- PR Newswire
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
